A Study to Compare the Effectiveness of Two Different Outpatient Endometrial Ablation Techniques Used for Heavy Periods (COAT)
Primary Purpose
Menorrhagia
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
NovaSure
thermachoice
Sponsored by
About this trial
This is an interventional treatment trial for Menorrhagia focused on measuring Heavy menstrual bleeding, menorrhagia, ThermachoiceTM, NovaSureTM, Endometrail Ablation
Eligibility Criteria
Inclusion Criteria:
- Women with no desire to preserve their fertility who have heavy menstrual bleeding without organic pathology (DUB) of more than six months duration
- Premenopausal follicular follicle stimulating hormone (FSH) level of less than 40 IU/L.
- Associated functional disability (negative impact on life quality).
- Lack of response to medical treatment.
- Prepared to undergo surgical treatment without general anaesthesia
Exclusion Criteria:
- Women under 25 years
- Suspected genital tract infection
- Uterine pathology including endometrial pathology on endometrial biopsy (e.g. endometrial hyperplasia or carcinoma) and structural lesions (e.g. uterine malformations, adhesions, polyps, submucous fibroids or extracavity fibroids > 3cm in diameter) as identified on pelvic ultrasound and/or outpatient hysteroscopy.
- Uterine cavity length >11cm
- Adnexal pathology
- Previous open myomectomy or endometrial ablation / resection and classical caesarian section
- patients considered vulnerable (e.g. current mental illness, emotionally labile, learning difficulties, immaturity)
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Other
Arm Label
novasure
thermachoice
Arm Description
Bipolar radio-frequency energy ablation of the endometrium by thermal therapy under impedance control. The bipolar current generated by the device produces a tapered depth of ablation with shallower ablation in the cornual regions / lower uterine segment and a deeper ablation in the mid-body of the uterus..
ThermachoiceTM III thermal balloon ablation
Outcomes
Primary Outcome Measures
Amenorrhoea
The objective of any treatment for HMB is to substantially reduce the amount of menstrual blood loss.Amenorrhoea rates are often chosen as the primary outcome measure in clinical trial of the effectiveness of endometrial ablation in women with HMB.
Secondary Outcome Measures
Visual analogue scale for assessment of pain
The main limitation of outpatient interventions is the amount of pain generated. Endometrial ablation has been shown to be feasible and generally well tolerated in conscious patients in small observational series10-11, but direct randomised comparisons between techniques regarding the amount of pain experienced during surgery are lacking
Full Information
NCT ID
NCT01124357
First Posted
March 18, 2010
Last Updated
May 14, 2010
Sponsor
Birmingham Women's NHS Foundation Trust
Collaborators
Hologic, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT01124357
Brief Title
A Study to Compare the Effectiveness of Two Different Outpatient Endometrial Ablation Techniques Used for Heavy Periods
Acronym
COAT
Official Title
A Randomised Control Trial To Compare the Effectiveness of Outpatient Endometrial Ablation Techniques (Novasure vs Thermachoice)in the Treatment of Menorhagia
Study Type
Interventional
2. Study Status
Record Verification Date
May 2006
Overall Recruitment Status
Completed
Study Start Date
May 2006 (undefined)
Primary Completion Date
October 2007 (Actual)
Study Completion Date
October 2008 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Birmingham Women's NHS Foundation Trust
Collaborators
Hologic, Inc.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
STUDY HYPOTHESIS: Does outpatient NovaSureTM endometrial ablation alleviate excessive menstrual bleeding and improve life quality more effectively than outpatient ThermachoiceTM endometrial ablation?
Detailed Description
Heavy menstrual bleeding (HMB) or 'menorrhagia' is a common condition with a major impact on health-related quality of life and health resource utilization in both primary and secondary care. In over 50% of cases no organic pathology is present and the term dysfunctional uterine bleeding (DUB) is used. First line treatment of DUB is medical and where this fails, surgery is indicated using either minimally invasive approaches (endometrial ablation) or major surgery (hysterectomy). Endometrial ablation has been extensively evaluated against the gold standard of hysterectomy and shown to be effective and associated with fewer complications. The technique involves destroying the entire, or a substantial proportion, of the endometrium thereby preventing cyclical endometrial regeneration and suppressing or reducing menstrual blood loss. Recent advances in endoscopic technology have resulted in the development of miniature, automated ablative systems (so called 'second generation devices'), which are easy to use, safe and obviate the need for routine unpleasant and expensive endometrial preparatory drugs10. Moreover, these devices have the potential to be routinely used in the outpatient or 'office' setting without the need for general anaesthesia. This approach is increasingly being advocated as it expands patient choice and potentially increasing safety and cost-effectiveness of treatment.
The three most commonly employed and evaluated ablative devices are ThermachoiceTM III thermal balloon ablation (Gynecare Inc, Somerville, NJ, USA), Microwave endometrial ablation (Microsulis plc, Waterlooville, Hampshire, UK) and NovaSureTM impedance-controlled endometrial ablation (Cytyc, Marlborough, MA USA). All appear to have comparable efficacy when employed as an inpatient under general anaesthesia in terms of patient satisfaction and life quality although data on direct head to head comparisons of these procedures when performed in an outpatient environment are scarce. All techniques have been employed without the need for general anaesthesia11,16-19, but only ThermachoiceTM has been reported in an outpatient setting11, without the need for formal theatre facilities or conscious sedation. The Microwave technique necessitates significant dilatation of the cervix that limits its potential for use in an outpatient setting in contrast to ThermachoiceTM and NovaSureTM10.
The newer NovasureTM system is more effective than ThermachoiceTM because inpatient studies report a higher rate of amenorrhoea (cessation of menstrual periods - 43% versus 8%). Moreover, NovaSureTM may be a better technique for use in conscious patients in an outpatient setting as it is a shorter procedure (1.5 versus 8 minutes) and associated with less post-operative pain16,19 but it does require a greater degree of potentially painful cervical dilatation10. There is thus a need for a randomised trial to compare the effectiveness and acceptability of ThermachoiceTM and NovaSureTM endometrial ablation in an outpatient setting for the treatment of menorrhagia.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Menorrhagia
Keywords
Heavy menstrual bleeding, menorrhagia, ThermachoiceTM, NovaSureTM, Endometrail Ablation
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
81 (Actual)
8. Arms, Groups, and Interventions
Arm Title
novasure
Arm Type
Active Comparator
Arm Description
Bipolar radio-frequency energy ablation of the endometrium by thermal therapy under impedance control. The bipolar current generated by the device produces a tapered depth of ablation with shallower ablation in the cornual regions / lower uterine segment and a deeper ablation in the mid-body of the uterus..
Arm Title
thermachoice
Arm Type
Other
Arm Description
ThermachoiceTM III thermal balloon ablation
Intervention Type
Device
Intervention Name(s)
NovaSure
Other Intervention Name(s)
Bipolar radio-frequency energy ablation
Intervention Description
Bipolar radio-frequency energy ablation of the endometrium by thermal therapy under impedance control. The bipolar current generated by the device produces a tapered depth of ablation with shallower ablation in the cornual regions / lower uterine segment and a deeper ablation in the mid-body of the uterus..
Intervention Type
Device
Intervention Name(s)
thermachoice
Other Intervention Name(s)
Thermal balloon ablation
Intervention Description
ThermachoiceTM III thermal balloon ablation
Primary Outcome Measure Information:
Title
Amenorrhoea
Description
The objective of any treatment for HMB is to substantially reduce the amount of menstrual blood loss.Amenorrhoea rates are often chosen as the primary outcome measure in clinical trial of the effectiveness of endometrial ablation in women with HMB.
Time Frame
6 months after the intervention.
Secondary Outcome Measure Information:
Title
Visual analogue scale for assessment of pain
Description
The main limitation of outpatient interventions is the amount of pain generated. Endometrial ablation has been shown to be feasible and generally well tolerated in conscious patients in small observational series10-11, but direct randomised comparisons between techniques regarding the amount of pain experienced during surgery are lacking
Time Frame
24 hours
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
25 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Women with no desire to preserve their fertility who have heavy menstrual bleeding without organic pathology (DUB) of more than six months duration
Premenopausal follicular follicle stimulating hormone (FSH) level of less than 40 IU/L.
Associated functional disability (negative impact on life quality).
Lack of response to medical treatment.
Prepared to undergo surgical treatment without general anaesthesia
Exclusion Criteria:
Women under 25 years
Suspected genital tract infection
Uterine pathology including endometrial pathology on endometrial biopsy (e.g. endometrial hyperplasia or carcinoma) and structural lesions (e.g. uterine malformations, adhesions, polyps, submucous fibroids or extracavity fibroids > 3cm in diameter) as identified on pelvic ultrasound and/or outpatient hysteroscopy.
Uterine cavity length >11cm
Adnexal pathology
Previous open myomectomy or endometrial ablation / resection and classical caesarian section
patients considered vulnerable (e.g. current mental illness, emotionally labile, learning difficulties, immaturity)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Justin Mr Clark, MD MRCOG
Organizational Affiliation
Birmingham Women's NHS Foundation Trust
Official's Role
Principal Investigator
12. IPD Sharing Statement
Citations:
PubMed Identifier
25004347
Citation
Smith PP, Malick S, Clark TJ. Bipolar radiofrequency compared with thermal balloon ablation in the office: a randomized controlled trial. Obstet Gynecol. 2014 Aug;124(2 Pt 1):219-225. doi: 10.1097/AOG.0000000000000395.
Results Reference
derived
PubMed Identifier
21173651
Citation
Clark TJ, Samuel N, Malick S, Middleton LJ, Daniels J, Gupta JK. Bipolar radiofrequency compared with thermal balloon endometrial ablation in the office: a randomized controlled trial. Obstet Gynecol. 2011 Jan;117(1):109-118. doi: 10.1097/AOG.0b013e3182020401.
Results Reference
derived
Learn more about this trial
A Study to Compare the Effectiveness of Two Different Outpatient Endometrial Ablation Techniques Used for Heavy Periods
We'll reach out to this number within 24 hrs